ISRCTN54157750 https://doi.org/10.1186/ISRCTN54157750

Randomised trial of neo-adjuvant therapy in patients with stage IIIA non small cell lung cancer

Submission date	Recruitment status	[_] Prospectively registered
28/02/2001	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
28/02/2001	Completed	[X] Results
Last Edited	**Condition category**	[_] Individual participant data
20/02/2020	Cancer	

Plain English summary of protocol
Not provided at time of registration

Study website
https://www.ctu.mrc.ac.uk/studies/all-studies/l/lu20/

Contact information

Type(s)
Scientific

Contact name
Dr Danielle Andrews

Contact details
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
-
abc@123.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
LU20

Study information

Scientific Title
-

Study objectives
To compare in patients with stage IIIA non small cell lung cancer a policy of standard therapy with thoracic radiotherapy versus a policy of chemotherapy followed, if feasible, by surgery

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration.

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Cancer

Interventions
1. One group receives standard therapy with thoracic radiotherapy
2. The other group receives chemotherapy followed, if feasible, by surgery

Intervention Type
Other

Phase
Phase III

Primary outcome measure

1. Survival time
2. Quality of life

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/09/1995

Completion date
01/05/1999

Eligibility

Key inclusion criteria
1. No previous treatment for the current lung cancer
2. Either sex
3. World Health Organisation (WHO) 0-2, T3N1M0 or T1-3N2M0 stage

Participant type(s)
Patient

Age group
Not Specified

Sex
Both

Target number of participants
350

Total final enrolment
48

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/09/1995

Date of final enrolment
01/05/1999

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Medical Research Council (MRC) (UK)

Sponsor details
20 Park Crescent
London
United Kingdom
W1B 1AL
+44 (0)20 7636 5422
clinical.trial@headoffice.mrc.ac.uk

Sponsor type
Research council

Website
http://www.mrc.ac.uk

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (MRC) (UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2005	20/02/2020	Yes	No